Group 1 - TD Cowen has raised the target price for Novartis (NVS.N) from $160 to $180 [1]

Core Viewpoint - UBS has raised the earnings per share forecast for Hua Hong Semiconductor (01347) for 2026 by 57% due to continuous improvement in product mix and a more favorable pricing environment, with the target price increased from HKD 80 to HKD 104 while maintaining a "Neutral" rating [1] Group 1: Financial Performance - Hua Hong's sales for Q4 2025 are projected to grow by 4% quarter-on-quarter to approximately USD 660 million, aligning with the company's guidance of USD 650 million to USD 660 million, driven by increased wafer shipments and higher average selling prices [1] - The gross margin for the period is expected to decline by 57 basis points quarter-on-quarter to 13%, which is within the guidance range of 12% to 14%, but below market expectations of 13.8%, primarily due to rising labor costs [1]

Group 1 - HSBC has raised the target price for Unilever from 4800 pence to 5100 pence [1]

Group 1 - Berenberg Bank raised the target price for Siemens Energy from €130 to €195 [1]

Core Viewpoint - RBC Capital raised the target price for Applied Materials from $385 to $430, while Morgan Stanley increased its target price from $364 to $420 [1] Group 1 - RBC Capital's new target price reflects a bullish outlook on Applied Materials' performance [1] - Morgan Stanley's adjustment indicates confidence in the company's growth potential [1]

Core Viewpoint - Cardina Health reported Q2 FY2026 revenue of $65.627 billion and net profit of $4.67 billion, both showing year-on-year growth and exceeding market expectations [1][2]. Financial Report Analysis - For Q2 FY2026, Cardina Health achieved revenue of $65.627 billion, representing an 18.75% year-on-year increase; net profit reached $4.67 billion, up 16.75% year-on-year. The growth was primarily driven by the pharmaceutical distribution business, although the gross margin was 3.52% and net margin was 0.71%, reflecting the low-margin nature of the industry. The revenue surpassed market expectations of $64.9381 billion, with earnings per share at $2.63, exceeding the forecast of $2.37 [2]. Institutional Perspectives - TD Cowen maintained a "Buy" rating for Cardina Health on February 11, 2026, raising the target price from $233 to $251 based on the better-than-expected performance and industry outlook. Among 20 institutions covering the stock in February, 80% rated it as "Buy" or "Hold," with an average target price of $251.13. The internal database indicates a forecast of $2.63 for Q2 earnings per share, reflecting a year-on-year increase of 36.27% [3]. Recent Events - The Q2 performance was disclosed on February 5, 2026. TD Cowen raised the target price on February 11, coinciding with a 1.05% overall increase in the healthcare sales sector [4]. Recent Stock Performance - Over the past 7 days (February 5 to 11), the stock price fluctuated by 4.94%, with a high of $230.81 on February 6 and a low of $219.58 on February 10. The closing price on February 11 was $224.25, reflecting a single-day increase of 1.81% with a trading volume of 1.3133 million shares. On February 6, trading volume peaked at 2.2507 million shares, indicating active trading that later declined. The internal database shows a price change of -1.29% during this period, primarily influenced by post-earnings volatility [5].

Group 1 - Jefferies raised the target price for GlobalFoundries from $37 to $46 [1]

Group 1 - The core viewpoint of the article is that Daiwa Capital Markets has raised the target price for Ford Motor Company (F.US) from $13 to $14 [1] Group 2 - The adjustment in the target price reflects a positive outlook on Ford's performance in the automotive market [1] - The new target price indicates a potential upside for investors considering Ford's stock [1] - This change may influence investor sentiment and trading activity related to Ford shares [1]

Group 1 - The target price for Ford Motor Company (F.N) has been raised from $13 to $14 by Daiwa Capital Markets [1]

Core Viewpoint - The analyst maintains a "Buy" rating for Grifols (GFF.N) and raises the target price from $100 to $108 [1] Institutional View - The analyst has a total success rate of 54.9% over the past year [2] Recent Events - Grifols will go ex-dividend on February 27, 2026, with a dividend of $0.22 per share; the record date is February 27, 2026, and the payment date is March 18, 2026 [3] Stock Performance - Over the last five trading days, Grifols' stock price has increased by 7.41%, closing at $91.01 on February 11, 2026, with a daily decline of 2.81%; year-to-date, the stock has risen by 23.56%, with a current P/E ratio (TTM) of 90.10 and a dividend yield of 0.88% [4]